Evidence-based treatment of anxiety disorders
- PMID: 24931539
- DOI: 10.1080/13651500600552487
Evidence-based treatment of anxiety disorders
Abstract
Evidence-based medicine combines the best currently available evidence from systematic medical research, together with clinical expertise, in order to provide the best available care for patients. In conjunction with systematic reviews (meta-analyses), a critical review of evidence-based literature forms the basis for the development of clinical treatment guidelines. Current treatment guidelines for generalized anxiety disorder (GAD) advocate the use of selective serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenaline reuptake inhibitors (SNRIs) as the first line of pharmacotherapy. The safety and tolerability profiles of other medications, such as the benzodiazepines, limit their use, especially for long-term treatment. Since data comparing the efficacy in GAD of different SSRIs are limited, selection of one SSRI over another is generally based on consideration of tolerability profiles. Treatment guidelines for patients with social anxiety disorder (SAD) often recommend SSRIs as the first line of medication treatment, as this class has the largest evidence-base in support of efficacy. Less consistent evidence of efficacy exists for other agents, such as reversible inhibitors of monoamine oxidase inhibitor A (RIMAs), and issues of safety are a concern when considering the use of benzodiazepines. Again, there are few head-to-head studies of the SSRIs, and treatment selection is usually made on the basis of tolerability issues. The efficacy and tolerability of the SSRI, escitalopram, has been evaluated in patients with GAD and with SAD. In long-term studies of SAD, escitalopram demonstrated superior efficacy to placebo and paroxetine. It also exhibited a better tolerability profile, as assessed by discontinuation emergent signs and symptoms (DESS), in both patient groups. Furthermore, in relapse prevention trials of SAD, escitalopram conferred a significant benefit relative to placebo.
Keywords: Anxiety disorders/drug therapy; SSRIs; evidence-based medicine; social phobia.
Similar articles
-
Generalized anxiety disorder: how to treat, and for how long?Int J Psychiatry Clin Pract. 2006;10 Suppl 1:10-5. doi: 10.1080/13651500600552396. Int J Psychiatry Clin Pract. 2006. PMID: 24931538
-
The importance of long-term tolerability in achieving recovery.Int J Psychiatry Clin Pract. 2006;10 Suppl 1:31-7. doi: 10.1080/13651500600552552. Int J Psychiatry Clin Pract. 2006. PMID: 24931542
-
Pharmacotherapy of social anxiety disorder: what does the evidence tell us?J Clin Psychiatry. 2006;67 Suppl 12:20-6. J Clin Psychiatry. 2006. PMID: 17092192 Review.
-
Paroxetine treatment of generalized anxiety disorder.Psychopharmacol Bull. 2003 Spring;37 Suppl 1:64-75. Psychopharmacol Bull. 2003. PMID: 14566202 Review.
-
New treatment options for OCD.Int J Psychiatry Clin Pract. 2007;11 Suppl 2:24-30. doi: 10.1080/13651500701388534. Int J Psychiatry Clin Pract. 2007. PMID: 24926869
Cited by
-
Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis.Am Heart J. 2015 Dec;170(6):1105-15. doi: 10.1016/j.ahj.2015.09.013. Epub 2015 Sep 21. Am Heart J. 2015. PMID: 26678632 Free PMC article. Review.
-
Perceived helpfulness of treatment for generalized anxiety disorder: a World Mental Health Surveys report.BMC Psychiatry. 2021 Aug 9;21(1):392. doi: 10.1186/s12888-021-03363-3. BMC Psychiatry. 2021. PMID: 34372811 Free PMC article.
-
Anxiety Symptoms Questionnaire (ASQ): development and validation.Gen Psychiatr. 2019 Dec 18;32(6):e100144. doi: 10.1136/gpsych-2019-100144. eCollection 2019. Gen Psychiatr. 2019. PMID: 31922090 Free PMC article.
LinkOut - more resources
Full Text Sources